Zobrazeno 1 - 10
of 10
pro vyhledávání: ''
Autor:
Marc Ladanyi, Mark G. Kris, Maria E. Arcila, Gregory J. Riely, Maureen F. Zakowski, Valerie W. Rusch, M. Catherine Pietanza, Camelia S. Sima, Christopher Lau, Paul K. Paik, Jamie E. Chaft
Publikováno v:
Molecular Cancer Therapeutics. 11:485-491
Phosphoinositide-3-kinase catalytic alpha polypeptide (PIK3CA) encodes the p110α subunit of the mitogenic signaling protein phosphoinositide 3-kinase (PI3K). PIK3CA mutations in the helical binding domain and the catalytic subunit of the protein hav
Autor:
Adi F. Gazdar, Hisao Imai, Junichi Soh, John D. Minna, Luc Girard, Jill E. Larsen, Mitsuo Sato, Yang Xie, Michael Peyton, Masatomo Mori, Noriko Yanagitani, Noriaki Sunaga, David S. Shames, Kyoichi Kaira
Publikováno v:
Molecular Cancer Therapeutics. 10:336-346
Oncogenic KRAS is found in more than 25% of lung adenocarcinomas, the major histologic subtype of non–small cell lung cancer (NSCLC), and is an important target for drug development. To this end, we generated four NSCLC lines with stable knockdown
Publikováno v:
Molecular Cancer Therapeutics. 8:2015-2026
Anticancer therapy with cisplatin and oxaliplatin is limited by toxicity and onset of tumor resistance. Both drugs form platinum-DNA cross-linked adducts, and cisplatin causes oxidative DNA damage including the 7,8-dihydro-8-oxo-2′-deoxyguanosine (
Publikováno v:
Molecular Cancer Therapeutics. 5:502-508
Irinotecan hydrochloride, a camptothecin derivative, is one of the most effective drugs for colorectal cancer, and SN-38 is its main active metabolite. Development of resistance is a major obstacle to the clinical application of this drug. We establi
Autor:
Anthony E. Pegg, Aparecida Maria Fontes, Marco Antonio Zago, Brian Davis, Lawrence A. Loeb, Dimas Tadeu Covas, Stanton L. Gerson, Lance P. Encell, Karen Lingas
Publikováno v:
Molecular Cancer Therapeutics. 5:121-128
P140K-MGMT and G156A-MGMT genes encode two O6-benzylguanine–resistant O6-alkylguanine DNA alkyltransferase proteins that confer a high degree of O6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) or O6-benzylguanine and temozolomide r
Autor:
Jennifer M. Kwan, Jody C. Chuang, Gangning Liang, Christine B. Yoo, Tony W.H. Li, Peter A. Jones, Allen S. Yang
Publikováno v:
Molecular Cancer Therapeutics. 4:1515-1520
DNA cytosine methylation plays a considerable role in normal development, gene regulation, and carcinogenesis. Hypermethylation of the promoters of some tumor suppressor genes and the associated silencing of these genes often occur in certain cancer
Publikováno v:
Molecular Cancer Therapeutics. 14:C65-C65
Background: Gene fusions involving members of the NTRK family have been identified in several types of cancer. The use of TRK inhibitors in vitro and in vivo have demonstrated activity against a number of different NTRK fusions in different tumor typ
Publikováno v:
Molecular Cancer Therapeutics. 10:B45-B45
Introduction: Change in the epigenetic pathways can alter level of gene expressions and trigger neoplastic transformation.1DNA methylation and histone modifications are two main epigenetic mechanisms that regulate gene expression. DNA demethylation r
Autor:
Sarah S. Bacus
Publikováno v:
Molecular Cancer Therapeutics. 10:PR-2
Somatic genetic mutation in the V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) gene has been linked to poor prognosis and resistance to various targeted therapeutics in Non Small Cell Lung Cancer (NSCLC). Therapeutic strategies that targ
Publikováno v:
Molecular Cancer Therapeutics. 8:C227-C227
Doxorubicin (DOX) is one of the most effective anticancer drugs in treating different types of tumors. However, cumulative cardiotoxicity is a significant side effect of this therapy resulting in clinical heart failure through the production of react